P-014 Efficacy and Safety of ABBV-383, a BCMA Bispecific Antibody, in Black Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of a Phase 1 Trial

IF 2.7 4区医学 Q2 HEMATOLOGY Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI:10.1016/S2152-2650(24)01917-7

Anita D'Souza, Cesar Rodriguez-Valdes, Shaji Kumar, Alfred Chung, Sascha Tuchman, Hana Safah, Katja Weisel, Raphael Teipel, Neha Korde, Ravi Vij, Orlando Bueno, Tanya Rosenberg, Rajvineeth Pothacamury, Akshanth Polepally, Aarif Ahsan, Shane Lee, Ziyi Jin, Shelli Spence, Chetasi Talati, John McKay, Peter M. Voorhees

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

P-014 ABBV-383（一种BCMA双特异性抗体）对复发性/难治性多发性骨髓瘤黑人患者的疗效和安全性：一期试验的亚组分析

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.